Traditionally, chemotherapy was given after surgery (primary cytoreductive surgery (PCRS) and adjuvant chemotherapy). However, chemotherapy can be used before surgery (neoadjuvant chemotherapy (NACT) ...

Furthermore, Ovarian Cancer Action revealed that only one in three women live more than 10 years after their diagnosis in the ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Ovarian tumors, often detected incidentally, pose a diagnostic challenge that requires careful management. Decisions depend on assessing the malignancy risk and addressing patient symptoms. For benign ...

The following is a summary of “Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population ...

A mathematical modeling study suggests that ovarian cancer incidence could be reduced and healthcare savings boosted if women who have already completed their families were offered fallopian tube ...

“These medicines will give people more treatment options and help them to live well for longer,” says Pharmac’s Director Equity and Engagement, Dr Nicola Ngawati. “We expect about 180 people will ...

Danelle Scalia never imagined that she would be fighting for her life against ovarian cancer at the age of just 41.But her ...

Losing her hair at 59 — a stark, visible sign of her struggle with ovarian cancer – was a “distressing” time for Victoria ...

Opportunistic salpingectomy (OS) during any suitable abdominal surgery is effective for reducing the incidence of ovari ...

Artificial intelligence (AI) models, particularly artificial neural networks and machine learning, outperform traditional methods in predicting post–complete cytoreduction outcomes in patients ...